@article{Creuzot-Garcher2022-mg,

title = {Incidence and prevalence of neovascular age-related macular 

 degeneration in France between 2008 and 2018: The LANDSCAPE 

 study},

author = {Catherine P Creuzot-Garcher and Mayer Srour and Florian Baudin and Vincent Daien and Corinne Dot and Sylvia Nghiem-Buffet and Jean-Francois Girmens and Nicolas Coulombel and Anne Ponthieux and Cecile Delcourt},

year  = {2022},

date = {2022-03-01},

journal = {Ophthalmol. Sci.},

volume = {2},

number = {1},

pages = {100114},

publisher = {Elsevier BV},

abstract = {Purpose: This study aimed to estimate the incidence and 

 prevalence of neovascular age-related macular degeneration 

 (nAMD) in the French population between 2008 and 2018. Design: 

 This was a retrospective, longitudinal population study using 

 health care consumption data from the Système National des 

 Données de Santé (SNDS; the French National Health 

 Information Database), which covers approximately 99% of the 

 French population. Participants: We identified individuals 

 treated for nAMD from the French population 50 years of age and 

 older. Identification criteria were nAMD diagnosis or 

 reimbursement of nAMD treatments (anti-vascular endothelial 

 growth factor intravitreal injection or dynamic phototherapy 

 with verteporfin). Exclusion criteria were high myopia, 

 diagnosis of other retinal diseases, and other treatments for 

 macular diseases (dexamethasone implant, laser therapy, etc.). 

 Methods: We calculated incidence and prevalence based on the 

 age-matched general population in France. Adjustment for age and 

 sex was also performed for incidence. Main Outcome Measures: 

 Incidence and prevalence of nAMD in the French population 

 between 2008 and 2018. Results: Between 2008 and 2018, we 

 identified 342 961 patients with nAMD (67.5% women). Mean $±$ 

 standard deviation age at nAMD diagnosis or first treatment 

 increased from 78.8 $±$ 8.1 years in 2008 to 81.2 $±$ 7.9 

 years in 2018. In 2018, annual incidence was 0.149% and 

 prevalence was 1.062% for the French population 50 years of age 

 or older. Incidence was stable over the 10-year period. Annual 

 incidence increased with age (0.223%, 0.380%, and 0.603% in 

 those 60 years of age or older, 70 years of age or older, and 80 

 years of age or older, respectively), with similar trends for 

 prevalence. No major differences were observed among the 14 

 regions of France for incidence or prevalence. Neovascular 

 age-related macular degeneration incidence in 2018 was not 

 impacted by the availability of primary or ophthalmology care in 

 patients' localities. Conclusions: The LANDSCAPE study provides 

 exhaustive nationwide data on incidence and prevalence of nAMD 

 in France over a 10-year period.},

keywords = {age-related macular degeneration; Age-related macular   degeneration; France; ICD-10, AMD, International Classification of   Diseases, neovascular age-related macular   degeneration, Syst{è}me National des Donn{é}es de Sant{é}   (National Health Information Database); VEGF, Tenth Revision; Incidence; Neovascular; Prevalence;   SNDS, vascular   endothelial growth factor; nAMD},

pubstate = {published},

tppubtype = {article}

}